FY2016 EPS Estimates for Celldex Therapeutics Inc. (CLDX) Cut by Analyst
Celldex Therapeutics Inc. (NASDAQ:CLDX) – Analysts at Leerink Swann dropped their FY2016 earnings estimates for shares of Celldex Therapeutics in a report issued on Tuesday. Leerink Swann analyst S. Fernandez now expects that the brokerage will post earnings per share of ($1.31) for the year, down from their previous forecast of ($1.25). Leerink Swann also issued estimates for Celldex Therapeutics’ Q4 2016 earnings at ($0.34) EPS and FY2017 earnings at ($1.15) EPS.
Several other analysts also recently weighed in on CLDX. Roth Capital set a $7.00 price target on Celldex Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 2nd. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Thursday. Wedbush restated a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a research note on Tuesday. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday. Finally, Jefferies Group restated a “hold” rating and issued a $5.00 target price (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $7.39.
Celldex Therapeutics (NASDAQ:CLDX) opened at 4.32 on Thursday. Celldex Therapeutics has a 12-month low of $2.85 and a 12-month high of $18.62. The stock’s market cap is $434.35 million. The firm’s 50-day moving average price is $3.66 and its 200 day moving average price is $4.04.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business earned $2.20 million during the quarter, compared to analysts’ expectations of $1.09 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The firm’s revenue for the quarter was up 115.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS.
Several institutional investors have recently made changes to their positions in the stock. Suffolk Capital Management LLC boosted its position in shares of Celldex Therapeutics by 8.9% in the second quarter. Suffolk Capital Management LLC now owns 474,799 shares of the biopharmaceutical company’s stock worth $2,084,000 after buying an additional 38,679 shares during the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of Celldex Therapeutics during the second quarter worth approximately $473,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Celldex Therapeutics by 4.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 373,066 shares of the biopharmaceutical company’s stock worth $1,638,000 after buying an additional 14,300 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of Celldex Therapeutics by 24.9% in the second quarter. Alps Advisors Inc. now owns 138,680 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 27,677 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Celldex Therapeutics during the second quarter worth approximately $188,000. 78.41% of the stock is owned by institutional investors and hedge funds.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.